Our Corporate Partners

The GIST Cancer Research Fund is a proud partner of Novartis and Pfizer Pharmaceutical Companies. With their very generous support throughout the years, we have the ability to spread awareness of GIST Cancer, help and assist patients and families who are coping with GIST, provide much needed funds to GIST Cancer doctors and researchers as well as share the same relentless goal to ultimately find a cure for GIST Cancer.

By definition, a rare disease affects just a small fraction of the population—fewer than 200,000 people in the United States and fewer than 1 in 2,000 in Europe. But the combined impact of rare diseases is significant. According to Global Genes, approximately 7,000 rare diseases affect an estimated 350 million people worldwide—more than the population of the United States.


Novartis works to improve the understanding of many rare diseases. In doing so, we’re not only helping patients who often have few treatment options, but also deepening knowledge of the molecular pathways that control multiple diseases. This may in time lead to new treatments for larger numbers of patients.

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.


Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers, including breast, lung, prostate, sarcoma, melanoma, and various hematologic cancers. Pfizer Oncology has biologics and small molecules in clinical development and more than 100 clinical trials underway. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough -4- medicines, to deliver the right drug for each patient at the right time.